@article{fdi:010083908,
  title = {{N}iclosamide shows strong antiviral activity in a human airway model of {SARS}-{C}o{V}-2 infection and a conserved potency against the {A}lpha ({B}.1.1.7), {B}eta ({B}.1.351) and {D}elta variant ({B}.1.617.2)},
  author = {{W}eiss, {A}. and {T}ouret, {F}. and {B}aronti, {C}{\'e}cile and {G}illes, {M}agali and {H}oen, {B}. and {N}ougairede, {A}. and {L}amballerie, {X}. de and {S}ommer, {M}. {O}. {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{SARS}-{C}o{V}-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. {N}iclosamide is a potent anti-{SARS}-{C}o{V}-2 agent that has advanced in clinical development. {W}e validate the potent antiviral efficacy of niclosamide in a {SARS}-{C}o{V}-2 human airway model. {F}urthermore, niclosamide remains its potency against the {D}614{G}, {A}lpha ({B}.1.1.7), {B}eta ({B}.1.351), and {D}elta ({B}.1.617.2) variants. {O}ur data further support the potent anti-{SARS}-{C}o{V}-2 properties of niclosamide and highlights its great potential as a therapeutic agent for {COVID}-19.},
  keywords = {},
  booktitle = {},
  journal = {{PL}o{S} {O}ne},
  volume = {16},
  numero = {12},
  pages = {e0260958 [8 ]},
  ISSN = {1932-6203},
  year = {2021},
  DOI = {10.1371/journal.pone.0260958},
  URL = {https://www.documentation.ird.fr/hor/fdi:010083908},
}